• Pfizer flagged late-breaking Phase 3 TALAPRO-3 results showing TALZENNA with XTANDI delayed disease worsening in a biomarker-defined group of metastatic castration-sensitive prostate cancer patients; data will be presented at ASCO May 29 to June 2, 2026 in Chicago.
• ASCO agenda also includes a late-breaking BREAKWATER readout indicating a BRAFTOVI-based first-line regimen improved outcomes in BRAF V600E-mutant metastatic colorectal cancer; presentation scheduled for May 31, 2026.
• Pfizer will also present a 7-year CROWN update that continues to support LORBRENA as a first-line option in ALK-positive metastatic non-small cell lung cancer; oral session set for May 29, 2026.
• Company plans additional updates on pipeline programs PF-08634404 and sigvotatug vedotin that back ongoing Phase 3 development in lung cancer; results will be presented during ASCO poster and rapid oral sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604211151BIZWIRE_USPR_____20260420_BW004885) on April 21, 2026, and is solely responsible for the information contained therein.